

2012 POAC National Board of Directors Meeting
Des Moines IA – 1PM – Jacobson Center
October 8-9, 2012

President Jackie Guthrie called the meeting to order at 8:00am, welcomed all visitors in attendance, and asked that roll call be taken: Jackie Guthrie, WI; Beverly Tabor, MD; Diana Peaton, AZ; Judy Katzenberger, WI; Dawn Walther, IL; Kathy McKenzie, OK; Harry Chestnut, MI; Pat Burton, TX, Todd Corn, IN; and Janette Arends, CO. At this time, Jeanette Krueger and C.Todd Corn were not in attendance. Director Sheila Bennett sent a letter to President Guthrie asking to be excused from this meeting due to personal work requirements. Discussion. **Director Tabor moved to excuse Director Bennett from this meeting. Director Arends seconded the motion. Unanimous. Motion passed.**

(Jeanette Krueger entered the meeting at this time)

Approval of the July 2012 POAC National Board of Directors Minutes –

Director Chestnut made a motion to approve the July 2012 Board Minutes as presented. Director Burton seconded the motion. Unanimous. Motion passed.

CEO Report – Joyse Banister gave a report to the Board on the following issues:

- Status of the office and the departments regarding work load and special projects
- 2012 POAC National Congress Overview – Very successful show with a good profit for the POAC and an excellent group of show personnel and staff...Looking forward to 2013
- New Website now up and running – New enhancements still being done
- Employee Evaluations completed with a report given to the POAC National President
- 2013 National Convention “A Day At The Race” – Planning is underway for this exciting event
- Illinois Special Olympics – sent POAC a thank you for the donation made at the Congress
- Recognized Leon Chastain’s passing on August 19, 2012

(C.Todd Corn joined meeting during this time)

Treasurers Report – Director Tabor presented the current financial statements to the Board for review. The Western Classic 2012 had a loss of about \$4,000. Discussion. This report will be filed subject to audit.

Department Reports – Stacey Stewart gave a brief report on the current status of the Bookkeeping Department. She reported that she is current on the mail received in the office, and is current on the month end reports for the Board. President Guthrie read reports from Kelly Gideon (Show Department) and Robin Robinett (Registration) and Tammy Virzi (Magazine) in their absence. Starting in the December POA Magazine, a monthly disclaimer will appear clarifying that opinions expressed by members and published in POA Magazine are not necessarily the opinions of the National Board or Staff.

Committee Reports –

International Futurity – Melissa Purkapile reported that the Futurity numbers appear to be strong, and several sponsorships have been obtained for the futurity classes. There will be a free potato-bake for everyone on Wednesday evening on the grounds.

International Sale – Susie Drish reported that there are 157 ponies consigned to the sale. On Saturday morning there will be a free pancake and sausage breakfast for everyone (as long as the food lasts) on the grounds. HYPP Testing was discussed and the POA National Office will continue to require testing verification as necessary on those found to have Impressive in the pedigree. Discussion regarding adding non-POA mares in foal to POA

Stallions to next year's sale as well as ID papered ponies. **Director Burton made a motion to allow the POA Sale Screening Committee to accept bred mares from POA approved Breeds in foal to Registered POA Stallions starting with the 2013 POA International Sale. Director Walther seconded the motion. Discussion. Voting in favor: Katzenberger, Walther, Tabor, Corn, Arends, McKenzie, Peaton, and Burton. Opposed were Chestnut and Krueger. Motion Passed. Director Burton made a motion to accept Blue and Pink ID papers ponies into the International Sale beginning in 2013. Director Walther seconded the motion. Discussion. Voting in favor: Tabor, Walther, Burton, Corn, Arends, Peaton. Opposed: Chestnut, Krueger, and McKenzie. Judy Katzenberger abstained. Motion passed.**

POA Youth Board – Director Walther gave a report for President Tyler Barringer in his absence. Youth Board balloting has been completed and now Tyler will be contacting those youth that received enough votes to be put in the Regional spots to see if they are willing to serve. There will be a Youth Meeting at the Sale on Friday evening.

Specialty Promotional Shows – After discussion of the three Specialty Promotional Shows currently approved by the POAC National Board of Directors, the following motions were made. **Director Chestnut made a motion to permit the Reichert Celebration to be approved by POAC for 2013-2015 as a Specialty Promotional Show and receive the same points as received in 2012 (three sets of "A" points and one set of overall Promotional type points as long as the show remains in Ft. Worth Texas. Director Burton seconded the motion. Voting in favor: Burton, Chestnut, Walther, Tabor, Corn, Arends, McKenzie, Krueger, and Peaton. Unanimous. Motion passed. (Katzenberger was absent during this vote).**

Director Burton made a motion to approve the NSBA "Show Your Colors" Show again for one year (2013) and to only allow one set of points (Promotional Points) from one judge only. Director Krueger seconded the motion. Voting in favor: Burton, Chestnut, Walther, Tabor, Corn, Arends, McKenzie, Krueger, and Peaton. Unanimous. Motion passed. (Katzenberger was absent during this vote)..

Director Corn made a motion to approve the Color Breed Congress Show for one year (2013) with the same points as 2012 (three sets of "A" points and one overall set of Promotional Type Points). Director Burton seconded the motion. Discussion. Voting in Favor: Walther, Burton, Corn, Chestnut, Arends, Krueger, McKenzie and Peaton. Tabor abstained. Motion Passed. (Katzenberger was absent during this vote).

OLD BUSINESS ---

Fee Change Proposal for 2013 and beyond –

CEO Joyse Banister proposed the following fee changes beginning in 2013. These fee increases are necessary to be able to fund the new Show Department, Registration, and Membership software being written for POAC. POAC fees have not been raised for several years and these increases are spread out over many areas. **Director Burton made a motion to accept the following fee increase schedule beginning January 1, 2013. All other fees not listed below will remain unchanged. Director McKenzie seconded the motion. Voting in favor: Tabor, Katzenberger, Walther, Burton, Corn, Chestnut, Arends, Peaton, and McKenzie. Opposed was Krueger. Motion Passed.**

Registration Department:

Registration: Weanlings (Jan 1 –Sept 30)	\$30
Weanlings (after Sept 30)	\$40
Yearlings	\$50
Two Years and Older	\$70
ID to Tentative	\$20
Tentative to Permanent	\$20

	Stallion to Gelding	\$5
	Annual Stallion Report	\$30
	Duplicate Certificate	\$20
	Duplicate PHC	\$25
Show Department:		
	Point 2-Year Detail Report	\$35
	Lifetime Summary	\$15
	One Year Summary	\$10
	ROM Individual Award	\$30
	Show Approval Fee (All Other)	\$40
	Pony Fees: IBC & B&P	\$7
	Ponyrama	\$3/\$5

Misc Fees:

Rush Fees:

	7 business days or less if paperwork is complete	\$150
	8 to 20 business days if paperwork is complete	\$100
	Less than 21 business days if paperwork is complete	\$35
Returned Check Fee		\$35

World Show Reinstatement – Discussion

Director Krueger made a motion to reinstate the World Show according to the proposal presented. Director Arends seconded the motion. Following more discussion, Krueger and Arends withdrew their motion and second to that this proposal could be revisited at the 2013 February Board Meeting.

Bad Check Policy for Affiliate POA Clubs – Discussion – No action taken

NHSR Partnership – Director Krueger gave this presentation after working with the Youth Rodeo organization personnel. NHSR made a POA Scholarship Application Form for the Board’s review. Krueger recommended that POA offer a scholarship to the Junior High group (14&U). POAC will give a \$200 scholarship. Jeanette and Omer Krueger have offered to match this amount for a total of a \$400 scholarship this time. NHSR will publish this on their website and their magazine. The Board thanked Jeanette for all of her hard work to make this program happen for both POA and NHSR. It is a win-win opportunity.

Points Program Proposal – Director Corn presented this to the Board for further discussion. Director Chestnut recommended that a letter go to the State Club Presidents for feedback on this issue so the Board can re-visit this at the February 2013 Board Meeting.

POAC Drug Rules – Rosslyn Biggs DVM gave a proposal to the Board for updating the current drug rules in the POAC Handbook. After discussion, **Director Walther made a motion to accept the following drug rule proposal to take effect and be fully implemented in 2014. Director Burton seconded the motion. More discussion. This would make a possible seminar topic for the 2013 or 2014 POA National Convention. Voting in favor: Arends, Krueger, Walther, McKenzie, Corn, Katzenberger, Tabor, Peaton, Chestnut, and Burton. Unanimous. Motion passed.**

The handling of a positive test will be dealt with on an individual case basis by the following process as needed:

1. Show Committee (or Futurity Committee)
2. Hearing Committee
3. Board of Directors

RULE 15: DRUGS AND MEDICATIONS-The Therapeutic Substance Provisions

A. Prohibited Substances - No person shall cause to be administered internally or externally to a pony, either before or during an approved event, any medication or drug which is of such character as could affect its performance or appearance at that event, **EXCEPT FOR THOSE CONDITIONALLY PERMITTED THERAPEUTIC MEDICATIONS, THE USE OF WHICH IS SPECIFICALLY PROVIDED FOR IN THE THERAPEUTIC MEDICATIONS SECTION (B) OF THIS RULE AND NOT OTHERWISE PROHIBITED BY GOVERNMENTAL REGULATIONS.** Upon discovery of administration of such drug or medication show management shall immediately report the matter to POAC. Any action or substance, administered internally or externally, whether drugs or otherwise, which may interfere with the testing procedure, or mask or screen the presence of such drug, is forbidden.

(1) Presence of such medication or drug in a horse participating in a POAC-approved event shall be grounds for the Executive Committee to take the following action if it is determined that the use of said drug or medication was not within the guidelines set forth in the following Therapeutic Medication section (B) of this rule:

(a) The pony shall be disqualified from all classes in which it participates at the show;

(b) Bar the pony from participation in further POAC-approved events or shows for such period as determined appropriate, and, upon request, the owner shall deliver the pony's registration certificate to POAC to be held during the period of the pony's suspension from participation. Although ownership of such pony may, thereafter, be transferred to another party, the transfer of ownership will not dissolve or shorten the terms of these suspensions; and

(c) The responsible individual as defined in this rule may be disciplined under POAC's general disciplinary procedure or may be offered an administrative penalty as determined appropriate by the Executive Committee.

(2) The below specified individuals are absolutely responsible for a pony's condition, are presumed to know all rules and regulations of POAC and the penalty provisions of said rules, and their voluntary action in presenting or causing the pony to be presented at show grounds for exhibition, entering a pony or exhibiting one in an approved show, and their absolute responsibility for the condition of the pony makes them eligible for disciplinary sanctions, whether or not they had actual knowledge of the presence of a forbidden drug, directly participated in the administration thereof, innocently miscalculated its retention time in the pony's system, or any other reason for its presence is established.

(3) It is presumed the sample of urine, saliva, blood or other substance tested by the laboratory is the one taken from the pony in question, its integrity is preserved, and that all procedures of such collection and preservation, transfer to the laboratory, and analysis of the sample are correct and accurate, and the report received from the laboratory pertains to the sample taken from the pony in question and correctly reflects the condition of the pony during the show in which he was entered, with the burden on the exhibitor or other responsible party to prove otherwise at any hearing in regard to the matter conducted by POAC.

(4) Pending final hearing by the Executive Committee or such other appropriate hearing committee, the Chief Executive Officer may, by giving written notice of his action to the owner of record at his current address as shown on POAC records, temporarily suspend such pony from further participation in an POAC-approved event or show.

(5) Every exhibitor shall, upon request of show management or POAC representative, permit a specimen of urine, saliva, blood or other substance to be taken for testing, and refusal to comply with such request shall constitute grounds for immediate disqualification of the pony from further participation at the show, shall bar the pony from participation in future POAC-approved events or shows for such period as determined by the Executive Committee or other appropriate committee, and shall constitute grounds for suspension of POAC membership. If the laboratory report on the chemical analysis of saliva, urine, blood or other sample taken from the pony indicates the presence of a forbidden drug or medication, this shall be taken as prima facie evidence such substance has been administered to the pony either internally or externally.

(6) An individual is absolutely responsible for a pony's condition if:

(a) he/she designates himself/herself on the entry blank as exhibitor, or authorizes another to designate him as exhibitor on the entry blank;

(b) he/she signs the entry blank on behalf of himself or another, or causes an agent or representative to sign it;

(c) he/she physically participates in the event by riding or showing the pony; or

(d) he/she is the actual trainer, having presented or caused to be presented the pony at the show grounds for exhibition. Both the exhibitor designated on the entry blank and one having actual possession of the pony while physically participating with the pony in the event are conclusively presumed to be authorized by the owner to execute all documents, necessary or convenient, to allow the pony's participation in an POAC-approved event, including documents pertaining to drug testing and the use of Lasix. If an individual is prevented from performing his/her duties, including absolute responsibility for the condition of the pony, by illness or otherwise, or is absent from the show, he/she shall immediately notify the show secretary, and appoint a substitute, and such substitute shall place his/her name on the entry blank forthwith. The exhibitor and owner acknowledge an exhibitor represents the owner in regard to his/her ponies entered in an approved show.

B. THERAPEUTIC MEDICATIONS (DOES NOT APPLY IF PROHIBITED BY GOVERNMENTAL REGULATIONS)

1. Forbidden drugs or substances:

(a) Any drug or substance considered a Class I or Class II substance as defined in the most recent edition of ARCI's Uniform Classification Guidelines for Foreign Substances.

(b) Any stimulant, depressant, tranquilizer or sedative which could affect the performance of a pony (stimulants and depressants are defined as substances that stimulate or depress the cardiovascular, respiratory or central nervous system).

(c) Any substance, regardless of how harmless or innocuous it might be, that might interfere with the detection or quantitation of any substance defined in (a)(b) or (c).

(d) Any anabolic steroid in halter classes.

(e) Any nonsteroidal anti-inflammatory drug (NSAID) other than those listed in section below.

(f) Any metabolite and/or analog of any of the above described forbidden drugs or substances.

2. EXHIBITORS, OWNERS, TRAINERS AND VETERINARIANS ARE CAUTIONED AGAINST THE USE OF MEDICINAL PREPARATIONS, TONICS, PASTES AND PRODUCTS OF ANY KIND, THE

INGREDIENTS AND QUANTITATIVE ANALYSIS OF WHICH ARE NOT SPECIFICALLY KNOWN, AS MANY OF THEM MAY CONTAIN A FORBIDDEN SUBSTANCE.

Conditionally permitted therapeutic medication: Any drug, medication or substance that could affect the performance of a pony that is used for the legitimate treatment of illness or injury and is not specified as a forbidden substance as defined in Section 1 above.

HOWEVER, THESE DRUGS OR SUBSTANCES ARE FORBIDDEN AND USE THEREOF SUBJECTS THE PERSON TO DISCIPLINARY ACTION, UNLESS ALL CONDITIONS OF THEIR ADMINISTRATION ARE MET.

Each of the following requirements is a condition to authorize administration of conditionally permitted therapeutic medications, which shall be verified in a written medication report, available from POAC or show management, completed in its entirety, and filed with show management before exhibition of the pony (see c through j below:

- (a)** Administration by a veterinarian who is licensed to practice veterinary medicine in the state, province or country where the event is being held or from a written prescription (written instructions) by a licensed veterinarian which documents administration of medication is necessary for the legitimate treatment of illness or injury. The administration of a conditionally permitted therapeutic medication for the purpose of transport, grooming, training, etc. is not therapeutic under this authorization rule.
- (b)** The pony must be withdrawn and kept out of competition for not less than 24 hours after the medication is administered.
- (c)** Identification of the medication: the name, amount, strength/concentration and mode of administration.
- (d)** Date and time of administration.
- (e)** Identification of the pony: name, age, sex, color and entry number.
- (f)** Diagnosis of illness/injury, reason for administration, and name of administering and/or prescribing veterinarian.
- (g)** Signature of veterinarian or person administering the medication. If by prescription (written instructions), a copy must be attached to the medication report.
- (h)** The medication report must be filed with show management within one hour after administration of the medication or one hour after show management is available, if administration occurs at a time other than during competition hours.
- (i)** The medication report must be signed by show management and time of receipt recorded on the report.
- (j)** While the medication report must be filed only if the administered medication will be present in amounts detectable in blood and/or urine samples at the time of competition/sampling, exhibitors are hereby cautioned it is their responsibility to determine whether or not such medication has had time to clear the pony's system. **IF THERE IS ANY DOUBT, A MEDICATION REPORT SHOULD BE FILED.**
- (k)** Regardless of whether the medication report requirements described above are met, laboratory detection of concentration levels of an otherwise conditionally permitted therapeutic drug that are inconsistent with the administration of a therapeutic dosage of such drug (including, but not limited to, inconsistencies regarding reported dosage and time constraints) shall constitute presumption of a violation of this rule, and the responsible party

has the burden of persuasion to establish that the drug was administered in a therapeutic dosage and not less than 24 hours prior to competition.

(I) Regardless of whether all of the conditionally permitted therapeutic medication requirements listed in Section 2 are met, it shall be considered a rule violation if the same plasma or urine sample contains more than one (1) of the permitted NSAIDs listed in section (3)(C)(1-8) below.

3. Restrictions Restrictions concerning the use of conditionally permitted therapeutic medications that may be administered within 24 hours of showing:

(A) Subject to the specified restrictions, only those thirteen (13) drugs or medications listed in section C below may be administered within 24 hours of showing. The provisions below contain rules concerning maximum allowable plasma concentration levels followed by "Guidelines".

The Guidelines are applicable to most ponies. Nevertheless, reliance upon the Guidelines does not guarantee compliance with the rules, since the response of individual horses may vary. Exhibitors, owners, and trainers should consult the drug manufacturer and knowledgeable veterinarians for up-to-date information and more specific advice concerning the therapeutic use of a drug or medication for a particular horse.

THE GUIDELINES, IF NEEDED, WILL MINIMIZE THE CHANCES OF POSITIVE DRUG TESTS. HOWEVER, ALL RESPONSIBLE PARTIES ARE CAUTIONED THAT THE GUIDELINES ARE ONLY GENERAL GUIDELINES, AND IT IS THEIR RESPONSIBILITY TO SEE TO IT THAT CONDITIONS PREVAIL FOR FULL COMPLIANCE WITH ALL AQHA RULES. RELIANCE UPON THE GUIDELINES WILL NOT SERVE AS A DEFENSE TO A CHARGE OF VIOLATION OF THE RULE IN THE EVENT OF A POSITIVE DRUG TEST.

Should the testing laboratory report the presence of one of the drugs or medications listed below in an amount greater than what would be consistent with the Guidelines or at a level higher than a specified maximum permitted plasma concentration, the matter will be reviewed and disciplinary action may be taken.

(B) Regardless of whether all of the conditionally permitted therapeutic medication requirements for a specific NSAID listed in Section C (1-13) below are met, it shall be considered a rule violation if the same plasma or urine sample contains more than one (1) of the NSAIDs listed in Section C(1-13) below.

(C) Only those thirteen (13) drugs or medications listed in Section C (1-13) below may be administered within 24 hours of showing:

C. Permitted Therapeutic Medications

(1) Phenylbutazone (an NSAID) - The maximum permitted plasma concentration of phenylbutazone is 15.0 micrograms per milliliter.

Guidelines: When phenylbutazone is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 2.0 milligrams per pound of body weight should be administered, preferably less. For a 1,000 pound animal, the maximum daily dose is 2.0 grams, which equals two 1.0 gram tablets, or two 1.0 gram units of paste, or 10.0 cc of the injectable (200 milligrams per milliliter). Neither a total daily dose nor part of an injectable dose should be administered during the 12 hours prior to competing. In the event the phenylbutazone is administered orally, half of the maximum daily dose (1.0 gram per 1,000 lbs) can be administered each 12 hours (i.e., 12 hours apart) during a five day

treatment program even if such oral administration occurs within 12 hours of competition. Phenylbutazone should not be used for more than five successive days.

(2) Diclofenac (Surpass) (an NSAID) - The maximum permitted plasma concentration of Diclofenac (Surpass) is 0.005 micrograms per milliliter.

Guidelines: Every 12 hours, not more than 73 mg of diclofenac liposomal cream should be administered (not more than 146 mg per 24 hour period) to one affected site. This 73 mg dose equals a 5-inch ribbon of cream not greater than 1/2 inch in width, which should be rubbed thoroughly into the hair over the joint or affected site using gloved hands. Administration of diclofenac cream should be discontinued 12 hours prior to competing. Do not apply diclofenac cream in

combination with any other topical preparations including DMSO, nitrofurazone or liniments, and do not use on an open wound. Diclofenac cream should not be administered for more than 10 successive days.

(3) Flunixin (an NSAID) - The maximum permitted plasma concentration of Flunixin is 1.0 microgram per milliliter.

Guidelines: When Flunixin Meglumine (Banamine®) is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 0.5 milligrams per pound of body weight should be administered. For a 1,000 pound animal, the maximum daily dose is 500 milligrams, which equals two 250 milligram packets of granules, or one 500 milligram packet of granules, or 500 milligrams of the oral paste (available in 1,500 milligram dose syringes), or 10.0 cc of the injectable (50 milligrams per milliliter). No part of a dose should be administered during the twelve (12) hours prior to competing. Any medicated feed must be consumed and/or removed at least twelve (12) hours prior to competing. The medication should not be used for more than five successive days.

(4) Ketoprofen (an NSAID) - The maximum permitted plasma concentration of Ketoprofen is 40.0 nanograms per milliliter.

Guidelines: When Ketoprofen (Ketofen®) is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 1.0 milligram per pound of body weight should be administered. For a 1,000 pound animal, the maximum daily dose is 1.0 gram, which equals 10.0 cc of the injectable (100 milligrams per milliliter). No part of a dose should be administered during the twelve (12) hours prior to competing. The medication should not be used for more than five successive days.

(5) Meclofenamic Acid (an NSAID) - The maximum permitted plasma concentration of Meclofenamic Acid (Arquel®) is 2.5 micrograms per milliliter.

Guidelines: When Meclofenamic Acid is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 12 hours, not more than 0.5 milligram per pound of body weight should be administered, preferably less. For a 1,000 pound animal, the maximum 12 hour dose is 0.5 gram, which equals one 500 milligram packet of granules. The medication should not be used for more than five successive days.

(6) Naproxen (an NSAID) - The maximum permitted plasma concentration of Naproxen is 40.0 micrograms per milliliter.

Guidelines: When Naproxen is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 4.0 milligrams per pound of body weight should be administered. For a 1,000 pound animal, the maximum daily

dose is 4.0 grams, which equals eight 500 milligram tablets. No part of a dose should be administered during the twelve (12) hours prior to competing. Any medicated feed should be consumed and/or removed at least twelve (12) hours prior to competing. The medication should not be used for more than five successive days.

(7) Firocoxib (Equioxx) (an NSAID) - The maximum permitted plasma concentration of Firocoxib (Equioxx) is 0.240 micrograms per milliliter.

Guidelines: When Firocoxib (Equioxx) is administered, the dose should be accurately calculated according to the actual weight of the animal. For a 1,000 pound animal, the maximum daily dose is 45.5 milligrams, which equals 0.1 milligram per kilogram of body weight once daily. No part of a dose should be administered during the 12 hours prior to competition. Firocoxib (Equioxx) should not be administered for more than 14 successive days.

(8) Eltenac (an NSAID) - (PENDING FDA APPROVAL – SEE BELOW) The maximum permitted plasma concentration of Eltenac is 0.1 microgram per milliliter.

Guidelines: When Eltenac is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 0.25 milligram per pound of body weight should be administered, preferably less. For a 1,000 pound animal, the maximum daily dose is 250 milligrams, which equals 5.0 cc of the injectable (50 milligrams per milliliter). No part of a dose should be administered during the 12 hours prior to competing. Eltenac should not be administered for more than five successive days. **ELTENAC HAS BEEN APPROVED FOR USE PENDING FDA APPROVAL. THIS MEDICATION MAY NOT BE USED UNTIL POAC HAS NOTIFIED MEMBERS AND EXHIBITORS OF THE FDA APPROVAL. PLEASE WATCH FOR STATEMENTS IN POAC PUBLICATIONS AND ON POAC'S WEB SITE AT POAC.ORG**

(9) Acetazolamide - may only be administered to horses documented through DNA testing to be positive (N/H or H/H) for HYPP (Hyperkalemic Periodic Paralysis). While these rules do not contain a maximum allowable plasma concentration level for Acetazolamide, laboratory detection of levels of Acetazolamide that are not consistent with administration in accordance with the following Guidelines may result in prosecution of a rule violation.

Guidelines: When acetazolamide is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 3 milligrams per pound of body weight should be administered. For a 1000 pound animal, the maximum daily dose is 3 grams.

(10) Furosemide or Lasix® - When used must be administered intravenously at least four hours prior to competition.

(11) Isoxsuprine - Guidelines: When administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 1.6 milligrams per pound of body weight should be administered (usually divided in two equal doses given 12 hours apart). For a 1,000 pound animal, the maximum daily dose is 1,600 milligrams, which equals 80 20-milligram tablets. No part of a dose should be administered during the four hours prior to competing. Any medicated feed should be consumed and/or removed at least four hours prior to competing.

(12) Lidocaine/Mepivacaine - may only be used under actual observation of event management (or designated representative) and/or the official show veterinarian, either of which must sign

the medication report form, to aid in the surgical repair of minor skin lacerations which, by their very nature, would not prevent the horse from competing following surgery. Medication report form must be filed with show management as required in section 2 above.

(13) Dexamethasone - The maximum permitted plasma concentration is 3.0 nanograms per milliliter at the time of competition.

Guidelines: In order to help trainers, owners and their veterinarians achieve compliance with this rule in connection with the therapeutic use of dexamethasone, it should be administered in accordance with the guidelines below. These guidelines include several alternative scenarios for dose time and route of administration. Whenever dexamethasone is administered, the dose should be accurately calculated according to the actual weight of the animal. Alternative Number 1. (2.0 mg or less per 100 pounds IV or IM at 12 or more hours before competition). Each 24 hours, not more than 2.0 milligrams of dexamethasone injectable solution per 100 pounds of body weight should be administered intravenously or intramuscularly, preferably less. For a 1,000 pound animal, the maximum daily intravenous or intramuscular dose of dexamethasone injectable solution is 20.0 milligrams, which equals 5.0 milliliters of the injectable solution (4.0 milligrams per milliliter). No part of this dose should be administered during the 12 hours prior to competing. Dexamethasone should not be administered for more than five successive days. Alternative Number 2. (0.5 mg or less per 100 pounds IV at 6 or more hours before competition). Each 24 hours, not more than 0.5 milligram of dexamethasone injectable solution per 100 pounds of body weight should be administered intravenously, preferably less. For a 1,000 pound animal, the maximum daily intravenous dose of dexamethasone injectable solution is 5.0 milligrams, which equals 1.25 milliliters of the injectable solution (4.0 milligrams per milliliter). No part of this dose should be administered during the six hours prior to competing. Dexamethasone should not be administered for more than five successive days. Alternative Number 3. (1.0 mg or less per 100 pounds orally at 6 or more hours before competition). Each 24 hours, not more than 1.0 milligram of dexamethasone powder per 100 pounds of body weight should be administered orally, preferably less. For a 1,000 pound animal, the maximum daily oral dose of dexamethasone powder is 10.0 milligrams, which equals one packet of dexamethasone powder (10.0 milligrams per packet). No part of this dose should be administered during the 6 hours prior to competing. Any medicated feed should be either consumed or removed at least six (6) hours prior to competing. Dexamethasone should not be administered for more than five successive days.

(14) Administration of these drugs does not require that the horse be withdrawn and kept out of competition for a period not less than 24 hours after the medication is administered, nor is there a requirement that a medication report be filed with show management, except when Lidocaine/Mepivacaine is used (see (12) above).

International Congress 2012 Report – Rosslyn Biggs and Harry Chestnut gave a report on the 2012 POA National Congress. Biggs reported that some issues that will be addressed when planning the 2013 Show include scheduling, selection of judges, use of an equipment judge, jumping practice, and some show rule clarifications. Biggs complemented the Ring Stewards and POA Staff for their work in making this show such a success. She also asked the Board to consider forming and implementing a Highly Contagious Disease Protocol for their National Events.

IBC Show Proposal (submitted from Terry Hollrich, OR) - This proposal would allow two IBC Shows to run concurrently on a weekend. Discussion. **Director Burton made a motion to approve, in addition to what we currently allow, the concurrent running of two IBC shows on a weekend. This would go into effect in 2014. Director Corn seconded the motion. Voting in favor: Burton, Peaton, and McKenzie. Opposed: Tabor, Katzenberger, Walther, Chestnut, and Arends. Abstain: Corn and Krueger. Motion Failed.**

Gant Lawsuit against POAC – President Guthrie reported to the Board that the position of POAC is favorable at this time. Trial date is currently set for February 2, 2013.

Hunter In Hand Class Added as a National Futurity Class – After discussion, **Director Burton made a motion to add Hunter In Hand as an International Futurity Class for 2013 and beyond. Ponies may be yearling through four years of age being shown by any-age handler. This will pay back ten placings. Director Katzenberger seconded the motion. Unanimous. Motion passed.**

JPFC and Other ROM Requirements – Referred back to Committee for a report in February 2013.

Director Burton made a motion to suspend the Mortitorium Rule for Rule 114. Director Corn seconded the motion. Voting in favor: Katzenberger, Walther, Burton, Corn, Chestnut, Arends, Krueger, and Peaton. Opposed: Tabor and McKenzie. Motion Passed

Director Burton made a motion to correct the current POAC Official Handbook and the Trail Score sheets to reflect that a disqualification is reflected as a zero score for the course. Director Krueger seconded the motion. Voting in favor: Katzenberger, Walther, Burton, Corn, Chestnut, Krueger, Arends, and Peaton. Opposed: Tabor Abstain: McKenzie Motion Passed.

Deceased Ponies – Rule 44 B. “When according to the POAC records a pony has lived twenty-five (25) years past January 1 of its foaling date, it will be presumed dead and its registration file will be automatically marked dead without necessity of prior notice. The pony is then ineligible for registration of its offspring foaled after that date or for participation in POAC approved events. If the pony has not actually died, and its owner wishes to reinstate its pedigree certificate, the owner may contact the POAC and provide satisfactory evidence that the pony is alive which the owner will be required to do on an annual basis.” – **Director Burton made a motion to delete this rule from the POAC Official Handbook. Director Peaton seconded the motion. Voting in favor: Katzenberger, Walther, Burton, Corn, Chestnut, Arends, Krueger, Peaton, Tabor, and McKenzie. Unanimous. Motion passed.**

N/H Mare Issue – Director Burton questioned the Board about a POA mare that was found to be N/H after she was already bred. For the resulting foal, are no current provisions to test the foal. This was referred to the Breeders Committee.

At this time the Board of Directors went into Executive Session.

Tuesday, October 9, 2012 – 8:00am

President Guthrie resumed the open session of the 2012 POAC National Board of Directors Meeting.
(Directors Arends and Krueger not present at this time)

President Guthrie recognized Directors Burton and Corn as outgoing Directors and thanked them for their service to the POAC. A gift of appreciation will be presented to them on Friday morning in the sale ring.

(Director Arends and Director Krueger joined the meeting at this time)

Director Tabor made a motion to have POAC CEO review the salaries of the staff as directed by the Board. Director Burton seconded the motion. Voting in favor: Katzenberger, Walther, Burton, Corn, Chestnut, Peaton, Tabor, Arends, Krueger, and McKenzie. Unanimous. Motion passed.

At this time President Guthrie seated the new Directors on the Board; Kristen Fears, TX, and Scott Shingleton, IN. She welcomed them to their new positions, and asked them to represent all POA members to the best of their ability.

Election of Officers ---

Nomination for President --- **Director Walther made a motion to nominate Jackie Guthrie for President. Director Katzenberger seconded the motion. Director Chestnut moved that nominations be closed. Director Krueger seconded the motion. Voting in favor: Katzenberger, Walther, Fears, Shingleton, Chestnut, Arends, Krueger, Peaton, Tabor and McKenzie. Unanimous. Motion passed.**

Director Walther made a motion to cast a unanimous ballot for Diana Peaton as Vice President and Beverly Tabor as Secretary/Treasurer. Director McKenzie seconded the motion. Voting in favor: Katzenberger, Walther, Fears, Shingleton, Chestnut, Arends, Krueger, Peaton, Tabor and McKenzie. Unanimous. Motion passed.

The Hearing Committee is elected by the Board of Directors and then the committee elects a chairman. After a paper ballot vote, the Hearing Committee is: Scott Shingleton, Harry Chestnut, Dawn Walther, Kristen Fears, and Judy Katzenberger (automatically on Hearing Committee as Chairman of the Rules Committee). The Hearing Committee reported to the Board that the Co-Chairmen of this Committee are Harry Chestnut and Judy Katzenberger.

Registration Department Policies for Changing Registration Papers from ID to Tentative or Permanent. The Board and CEO discussed the problems encountered when an owner wants an immediate change of papers from ID to Tentative or Permanent once issued. The Registrar is registering these ponies based on photos submitted to the office. To make this immediate change in papers, the office policy has been temporarily amended to require three National Inspectors (for Tentative) or three National Directors (for Permanent) to complete and submit Inspection Forms within a specific time frame to allow papers to be changed immediately. The policy temporarily implemented and requiring Board approval for permanent implementation is as follows:

To go from ID to Tentative - If time has passed for the animal to possibly change color/characteristics, the registrar can look at new photos and process, if warranted. If the owner wants the ID papers changed immediately, the pony must be inspected by three National Inspectors and all three POA Inspection Forms must be submitted to the POAC within 30 days of the request, along with a new set of photos, indicating that this pony qualifies for Tentative papers. These inspection may be done at different times, but must be submitted immediately after the inspection has been conducted and within the 30 days of request.

If a pony is Tentative and has been inspected for Permanent Papers, and the Registrar does not see enough color/characteristics to advance to Permanent papers, then three National Directors must inspect this pony and must submit POAC Inspection Forms to the registrar. These inspections may be done, but must be submitted immediately after the inspection has been conducted and within 30 days of request, indicating that either this pony does or does not qualify for Permanent papers before this pony will be advanced to permanent.

When the Registrar and the POAC CEO determines that a pony has questionable color/characteristics from photographs submitted with paperwork, the Registrar will scan and forward these photos (with an assigned reference number) to the Executive Committee for their review and recommendations. This Committee is made up of three National Directors that are also National Inspectors, and includes the President, Vice-President, and Secretary/Treasurer.

If a member needs their paperwork back within 21 business days, the current POAC Rush Fee will be charged. Depending on the time of year, they may get their paperwork back in fewer than 21 business days, but the Registration Department has 21 business days to finish all rush paperwork and still be in the bounds of the rush fee time frame. Keep in mind that this applies to paperwork that is originally submitted complete, and photos do not need to be sent to the Executive Committee for review. The POAC will make every effort to accommodate the needs of the membership when requesting paperwork back for specific events.

Director Katzenberger made a motion to accept this policy as amended to include past or present National Directors for going from ID to Permanent. Director Walther seconded the motion. Voting in Favor: Tabor, Katzenberger, Walther, McKenzie, Shingleton, and Peaton. Opposed: Chestnut, Arends, Krueger, and Fears. Motion Passed.

POAC Royalty – A proposal was reviewed by the Board to offer a POAC Royalty Program at the National Congress Show. After discussion, this was referred to the Youth Committee.

National Director Term Limits Proposal – President Guthrie asked the Directors to consider making term limits for National Directors. Discussion. She asked the Directors to poll their regions about this and report back to the Board in February 2013.

International Futurity Fee Schedule – No action taken

National Inspector Applicants – None at this time

Director Tabor discussed the idea of a POA Graduate taking their junior pony into the JPFC for their first year in that program. This was referred to the JPFC Futurity Committee for review.

Director Chestnut asked for Director input regarding the idea of not allowing JPFC ponies to enter in the 19 & Over classes. Discussion.

The Board heard from Holly Deschenes, WI requesting consideration of an Amateur Program for POAC. Discussion.

Director McKenzie asked the Board to consider a proposal requiring nominees for National Director to be able to complete the National Inspector process within one year after coming onto the Board. Discussion.

International Show vs. International Congress – Director Chestnut made a motion to the Board to keep the POAC National Congress title instead of POAC International Show. Director Peaton seconded the motion. Voting in favor: Tabor, Katzenberger, Walther, McKenzie, Shingleton, Peaton, and Chestnut. Opposed: Krueger, Arends and Fears. Motion Passed.

International Show Manager for 2013 – Director Chestnut made a motion that the CEO and Congress Show Committee enter into negotiations to re-hire Scott Biggs, OK, for the Show Manager position at the 2013 POAC National Congress Show and to suspend the Rule 67K (last sentence referring to immediate family as it pertains to Leadline Equitation) for 2013. Director McKenzie seconded the motion. Discussion. Voting in favor: Katzenberger, Walther, McKenzie, Shingleton, Peaton, Chestnut, Arends, and Fears. Opposed: Krueger Abstained: Tabor. Motion Passed.

Director Tabor asked if the Board would consider a poll of the membership to see if a majority would be in favor of raising the POA height limit for mature ponies to 58". Discussion. A poll sheet will be prepared and sent to the Board for them to poll the members in their regions and report back in February 2013.

Director Peaton asked the Board to set a fee for duplicate PHCs because this fee is not listed in the Official Handbook. **Director Peaton made a motion to make duplicate PHCs \$25 each. Director Fears seconded the motion. Discussion. Voting in favor: Unanimous. Motion passed.**

Director Peaton asked the Board to consider registering ID foals for free if done within the first 6 months of age. This was referred to the Breeders Committee.

Executive Session at this time.

The meeting was re-opened by President Guthrie. **Director McKenzie made a motion for the POAC Registrar to send a letter of concern regarding inspection of a pony via e-mail. Director Chestnut seconded the motion. Voting in favor: Tabor, Katzenberger, Walther, McKenzie, Shingleton, Peaton, Chestnut, Krueger, Arends and Fears. Unanimous. Motion Passed.**

POAC National Congress Show Site for 2014-2016 – Two proposals were reviewed and discussed by the Board. The National Equestrian Center in Lake St. Louis Missouri and Tulsa Fairgrounds in Tulsa Oklahoma were both discussed in great length by the Board. Fees were compared and the results of the 2012 National Congress Survey cards was considered. **Director Arends made a motion to go to Tulsa for three years beginning in 2014 for the POAC National Congress Show. Director Fears seconded the motion. Discussion. Voting in favor: Arends, Fears, Krueger, McKenzie, and Peaton. Opposed: Tabor, Katzenberger, Walther, Chestnut and Shingleton, and Guthrie. Motion Failed. Director Walther made a motion to go to the National Equestrian Center in Lake St. Louis Missouri for 2014-2016. Director Tabor seconded the motion. Discussion. Voting in favor: Tabor, Katzenberger, Walther, Chestnut, Krueger and Shingleton. Opposed: Fears, Arends, McKenzie, and Peaton. Motion passed.**

Director Chestnut made a motion to adjourn the meeting. Director Krueger seconded the motion. Unanimous. Motion passed.

Respectfully Submitted,

Joyse L. Banister
CEO/POA